Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Gilead Sciences (Nasdaq: GILD) has announced that it will release its second quarter 2024 financial results on Thursday, August 8, 2024, after the market closes. The company's management will host a webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. A live webcast will be available on the Investor Relations section of www.gilead.com and will be archived for one year.
Gilead Sciences is a biopharmaceutical company with over three decades of experience in developing breakthrough medicines. The company focuses on innovative treatments for life-threatening diseases such as HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with its headquarters in Foster City, California.
Gilead Sciences (Nasdaq: GILD) ha annunciato che pubblicherà i suoi risultati finanziari del secondo trimestre 2024 il giovedì 8 agosto 2024, dopo la chiusura del mercato. La direzione dell'azienda ospiterà un webcast alle 16:30 ora orientale per discutere i risultati e fornire aggiornamenti sull'azienda. Un webcast in diretta sarà disponibile nella sezione Relazioni con gli Investitori di www.gilead.com e sarà archiviato per un anno.
Gilead Sciences è un'azienda biofarmaceutica con oltre tre decenni di esperienza nello sviluppo di medicinali innovativi. L'azienda si concentra su trattamenti innovativi per malattie potenzialmente letali come HIV, epatite virale, COVID-19 e cancro. Gilead opera in oltre 35 paesi in tutto il mondo, con sede a Foster City, California.
Gilead Sciences (Nasdaq: GILD) ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 el jueves 8 de agosto de 2024, después del cierre del mercado. La gerencia de la compañía presentará un webcast a las 4:30 p.m. hora del Este para discutir los resultados y proporcionar una actualización comercial. Se podrá acceder a un webcast en vivo en la sección de Relaciones con Inversores de www.gilead.com y se archivará por un año.
Gilead Sciences es una empresa biofarmacéutica con más de tres décadas de experiencia en el desarrollo de medicamentos innovadores. La compañía se centra en tratamientos innovadores para enfermedades potencialmente mortales como VIH, hepatitis viral, COVID-19 y cáncer. Gilead opera en más de 35 países de todo el mundo, con sede en Foster City, California.
길리아드 사이언스(Gilead Sciences, Nasdaq: GILD)는 2024년 2분기 재무 결과를 2024년 8월 8일 목요일 시장 종료 후 발표할 것이라고 발표했습니다. 회사 경영진은 동부 표준시 기준 오후 4시 30분에 결과에 대해 논의하고 비즈니스 업데이트를 제공하기 위해 웹캐스트를 주최할 예정입니다. 실시간 웹캐스트는 www.gilead.com의 투자자 관계 섹션에서 이용할 수 있으며, 1년간 저장됩니다.
길리아드 사이언스는 30년 이상의 경험을 가진 생명공학 제약 회사입니다. 이 회사는 HIV, 바이러스성 간염, COVID-19, 암과 같은 생명을 위협하는 질병에 대한 혁신적인 치료법에 집중하고 있습니다. 길리아드는 전 세계 35개국 이상에서 운영되며, 본사는 캘리포니아주 포스터 시티에 있습니다.
Gilead Sciences (Nasdaq: GILD) a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le jeudi 8 août 2024, après la fermeture du marché. La direction de l'entreprise animera un webcast à 16h30 heure de l'Est pour discuter des résultats et fournir une mise à jour commerciale. Un webcast en direct sera disponible dans la section Relations avec les Investisseurs de www.gilead.com et sera archivé pendant un an.
Gilead Sciences est une entreprise biopharmaceutique avec plus de trois décennies d'expérience dans le développement de médicaments révolutionnaires. L'entreprise se concentre sur des traitements innovants pour des maladies potentiellement mortelles telles que VIH, hépatite virale, COVID-19 et cancer. Gilead opère dans plus de 35 pays dans le monde, avec son siège à Foster City, Californie.
Gilead Sciences (Nasdaq: GILD) hat angekündigt, dass es seine Finanzberichte für das zweite Quartal 2024 am Donnerstag, den 8. August 2024, nach Marktschluss veröffentlichen wird. Das Management des Unternehmens wird um 16:30 Uhr Eastern Time einen Webcast veranstalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben. Ein Live-Webcast wird im Bereich Investor Relations von www.gilead.com verfügbar sein und für ein Jahr archiviert werden.
Gilead Sciences ist ein biopharmazeutisches Unternehmen mit über drei Jahrzehnten Erfahrung in der Entwicklung bahnbrechender Medikamente. Das Unternehmen konzentriert sich auf innovative Behandlungen für lebensbedrohliche Krankheiten wie HIV, Virushepatitis, COVID-19 und Krebs. Gilead ist in mehr als 35 Ländern weltweit tätig, mit Hauptsitz in Foster City, Kalifornien.
- None.
- None.
A live webcast will be available on the Investor Relations section of www.gilead.com and will be archived there for one year.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724124310/en/
Jacquie Ross, CFA – Investors
investor_relations@gilead.com
Source: Gilead Sciences, Inc.
FAQ
When will Gilead Sciences (GILD) release its Q2 2024 financial results?
What time is Gilead Sciences' (GILD) Q2 2024 earnings webcast scheduled for?
Where can I access Gilead Sciences' (GILD) Q2 2024 earnings webcast?
What are the main therapeutic areas Gilead Sciences (GILD) focuses on?
